OPKO HEALTH, INC.
No SEC Form 4 filings for $OPK in the last 30 days.
See all $OPK insider activity →OPKO HEALTH, INC. (OPK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement . On October 14, 2026, OPKO Health, Inc., a Delaware corporation (“ OPKO ”), its wholly owned subsidiary, BioReference Health, LLC (“ BioReference ” and together with OPKO, “ Seller ”), and Laboratory Corporation of America Hol
Tel Aviv indices saw mixed performance. The Tel Aviv 35 Index fell 0.15%, while the BlueTech Global Index rose 0.21%. Tower Semiconductor dropped 7.61%, and Opko Health surged 26.64% after announcing a $722M asset sale. Electra Real Estate rose 25.30% following a NIS 95M injection.
Labcorp (LH) will acquire select assets of BioReference Health, OPKO Health's (OPK) subsidiary, for $722M, with up to $150M more in earnouts. The deal includes BioReference's clinical and women's health testing services, urology, corrections, and the 4Kscore Test. Labcorp expects $250M in first-year revenue from the acquired business, subject to regulatory approval.
Over the past 7 days, AlphAI's AI scored 14 news stories mentioning OPK (OPKO HEALTH, INC.). Coverage has skewed bullish: 9 bullish, 3 neutral, and 2 bearish.
Recent OPK coverage spans corporate actions, market movers and mergers & acquisitions.
Deal announcement creates near-term execution and closing-risk focus for OPKO, with potential earnings impact from divestiture proceeds and contingent consideration.
Deal proceeds and contingent earn-out tied to 4Kscore revenue should support sentiment, but the contingent nature adds uncertainty.
Sell pressure as OPKO divests a revenue‑generating unit.
Conversion will increase share count, likely diluting existing shareholders and putting downward pressure on OPK.
Conversion will increase share count, creating dilution pressure on existing shareholders.
AlphAI scores every news story that mentions OPK with an AI model for sentiment and relevance, and aggregates insider trades from OPKO HEALTH, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
OPKO HEALTH, INC. (OPK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement . On October 14, 2026, OPKO Health, Inc., a Delaware corporation (“ OPKO ”), its wholly owned subsidiary, BioReference Health, LLC (“ BioReference ” and together with OPKO, “ Seller ”), and Laboratory Corporation of America Hol
6 min readTel Aviv indices saw mixed performance. The Tel Aviv 35 Index fell 0.15%, while the BlueTech Global Index rose 0.21%. Tower Semiconductor dropped 7.61%, and Opko Health surged 26.64% after announcing a $722M asset sale. Electra Real Estate rose 25.30% following a NIS 95M injection.
6 min readLabcorp (LH) will acquire select assets of BioReference Health, OPKO Health's (OPK) subsidiary, for $722M, with up to $150M more in earnouts. The deal includes BioReference's clinical and women's health testing services, urology, corrections, and the 4Kscore Test. Labcorp expects $250M in first-year revenue from the acquired business, subject to regulatory approval.
2 min readOPKO Health's stock (OPK) surpassed $1.495, triggering convertibility of $121M in 3.75% Convertible Senior Notes due 2029. Holders can convert notes into 869.5652 shares per $1,000 principal until Dec 31, 2026. The company will satisfy conversions with common stock, per its SEC filing.
1 min readOPKO HEALTH, INC. (OPK) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events . On October 1, 2026, OPKO Health, Inc. (the “Company”) determined that its 3.75% Convertible Senior Notes due 2029 (the “Notes”), of which approximately $121 million is outstanding, are convertible by holders of such Notes through December 31, 2026. The Co
1 min readOPKO Health (OPK) issued $125M in senior secured notes to HealthCare Royalty, backed by royalties from mazdutide sales in China. The notes mature in 2044, with payments capped at 1.5x the royalty amount. OPKO reported Q2 revenue of $163.5M, up from $156.8M a year earlier, and a net loss of $8.4M, improved from a $148.4M loss. Diagnostics revenue fell to $74.5M due to asset sales. OPK repurchased $13.2M in stock while maintaining $314.4M in cash and securities.
3 min readOPKO Health is focusing on therapeutics, integrating ModeX Therapeutics and advancing programs in obesity, growth disorders, and oncology. The company expects significant clinical data in 12-18 months, with catalysts including updates on ModeX candidates and Merck's EBV vaccine. OPKO has $400M-$450M in cash, $125M from a China GLP-1 royalty, and plans a $200M share buyback.
2 min readCocrystal Pharma (COCP) appointed Robert Sapirstein as CEO, with a compensation package tied to performance and equity. Phillip Frost, chairman of OPKO Health (OPK), invested $5 million in COCP. The company's board includes notable figures with pharmaceutical and corporate experience. COCP's antiviral candidate, CDI-988, is in Phase 1b trials with FDA Fast Track designation, targeting norovirus and other viruses. The company has $7.1 million in cash, providing a runway until Q1 2024.
3 min readOPKO Health (OPK) is positioned for growth due to RAYALDEE's performance and strategic partnerships. The company anticipates 23.3% earnings growth by 2026 and has outperformed the industry and S&P 500 year-to-date. However, risks include overdependence on RAYALDEE, clinical development risks, and macroeconomic pressures. OPK's shares have gained 17.4% YTD.
3 min readOPKO Health (OPK) trades at a discount to industry benchmarks, with improving operating trends but ongoing losses. Q2 2026 loss narrowed to $0.01 per share, and full-year loss is expected to improve. OPK has multiple clinical programs in development, with partnerships reducing funding burdens. Cash reserves stand at $314.4 million. Analysts suggest a wait-and-see approach due to mixed risk-reward profile.
2 min read
